CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered ...

McCarthy expects a "CX-2051 data update in Q1 of next year" and highlighted that "investing behind a potential first approval will continue to be our top capital allocation priority." The company ...